Minimal residual disease as biomarker for optimal biologic dosing of ARA‐C in patients with acute myeloid leukemia

E-ISSN： 1096-8652|90|2|125-131

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.90, Iss.2, 2015-02, pp. : 125-131

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia

CANCER, Vol. 119, Iss. 22, 2013-11 ,pp. : 4036-4043

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pilot Remission Induction Therapy with Idarubicin, plus an Intensified Dose of Ara-C and Priming with Granulocyte Colony-Stimulating Factor for Acute Myeloid Leukemia

Acta Haematologica, Vol. 117, Iss. 2, 2006-11 ,pp. : 109-114

Karger

Access to resources Recommend Favorite

Detection of Minimal Residual Disease in Acute Myelogenous Leukemia

Acta Haematologica, Vol. 112, Iss. 1-2, 2004-06 ,pp. : 40-54

Karger

Access to resources Recommend Favorite

Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease

Acta Haematologica, Vol. 135, Iss. 3, 2015-11 ,pp. : 133-139

Karger

Access to resources Recommend Favorite

Immunological Detection of Minimal Residual Disease in Acute Lymphoblastic Leukemia

Oncology Research and Treatment, Vol. 24, Iss. 5, 2001-10 ,pp. : 442-448

Karger

Access to resources Recommend Favorite